Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Acromegaly was defined as a syndrome by Pierre Marie in 1885, but in the form of either
acromegaly or acrogigantism has probably been a disorder of antiquity [1, 2]. It is one of the …

Context: An association between germline aryl hydrocarbon receptor-interacting protein
(AIP) gene mutations and pituitary adenomas was recently shown. Objective: The objective …

Approximately 40% of growth hormone–secreting pituitary adenomas have somatic
mutations in the GNAS1 gene (the so-called gsp oncogene). These mutations at codon 201 …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …

Context Somatotroph adenomas have been classified into densely granulated (DG) and
sparsely granulated (SG) tumours with a transitional, intermediate group. Gsp oncogenes …

Objective To evaluate the efficacy, safety and tolerability of octreotide LAR®(long‐acting
repeatable octreotide) in the primary therapy of acromegaly. Design and patients Ninety …

Acromegaly (ACM) is a chronic, progressive disorder caused by the persistent
hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The …

Context: Somatostatin receptor subtype 2 (sst2A) protein expression has been demonstrated
to positively correlate with somatostatin analog treatment outcome in GH-secreting …